Biostatistical Methods for System Modeling

Biostatistics & Machine Learning: Bridging Disciplines to Decode Cancer Progression 🧬📊🤖 The integration of biostatistics and machine learning (ML) is opening unprecedented avenues in oncological research, from decoding early cellular changes to predicting patient outcomes. 🧠 From Hypothesis-Driven Models to Data-Driven Discovery 🔍 Biostatistics remains the backbone of clinical inference: • Framing clear research questions • Designing trials and population studies • Controlling for confounding and ensuring internal validity 🤖 Machine Learning complements this by: • Modeling non-linear, high-dimensional relationships • Detecting hidden patterns in multi-omics, imaging, and EHR data • Enabling continuous learning from real-world inputs 🧬 Biological Theory Meets Algorithmic Precision Cancer is not random—it follows biological rules. Combining statistical frameworks with mechanistic understanding allows us to: • Align ML feature importance with known carcinogenesis pathways (e.g., initiation, promotion, progression) • Use longitudinal data to map disease trajectories • Apply causal inference tools (e.g., g-methods, mediation analysis) within ML pipelines 📌 Example: SHAP values in ML can highlight gene-environment interactions, guiding biomarker discovery with statistical rigor. 🛠 Tools of the Trade • 📈 Biostatistics: Generalized linear models, survival analysis, mixed models • 🤖 ML Methods: XGBoost, Random Forests, Deep Neural Networks • 🔍 Interpretability: SHAP, LIME, ICE plots • 🧪 Validation: Bootstrapping, cross-validation, decision curve analysis ⸻ 🚧 Challenges & 🚀 Opportunities in the Nordic Context Challenges: • Need for cross-disciplinary fluency (stats ↔ bioinformatics ↔ ML) • Overfitting risk in small-to-moderate sample sizes • Regulatory and ethical hurdles for AI deployment in health Opportunities: • Access to population-wide registries (e.g., Cancer Registry of Norway) • Integration of biobank data, lifestyle surveys, and clinical records • Open science and reproducibility culture 💡 The Way Forward: Precision Prevention & Predictive Oncology Combining epidemiologic insight, statistical robustness, and ML adaptability will be crucial for next-generation cancer research. This integrated approach doesn’t just describe risk—it helps forecast and intercept it. 🧠 Let’s move from merely detecting cancer to understanding its evolution, and from descriptive analytics to actionable intelligence. 🔗 Are you working at the intersection of biostatistics and machine learning in Norway or Scandinavia? Let’s connect and exchange insights. #CancerResearch #Biostatistics #MachineLearning #Epidemiology #PrecisionMedicine #AIinHealthcare #Oncology #NorwayScience #CausalInference #PublicHealth #DataScience #SHAP #SurvivalAnalysis

Understanding counts in epidemiology, public health, and demography is as crucial as counting itself. Poisson regression helps predict events like disease incidence, hospital visits, and mortality rates by assuming a constant event rate. But real-world data is rarely that simple—overdispersion can break the model’s assumptions. That’s where negative binomial regression steps in, handling variability when risks aren’t evenly distributed. These models guide disease surveillance, resource allocation, and policy decisions. Whether tracking tuberculosis mortality trends or predicting HPV-related cancer risks, the right statistical approach turns raw data into actionable insights that save lives. Public health isn’t just about collecting data—it’s about making sense of it.

📊 Advanced alternatives to logistic regression for modeling the prevalence of binary outcomes! 📊 Are you ready to explore advanced alternatives to logistic regression for modeling the prevalence of binary outcomes? Dive into these top methods and revolutionize your biostatistics research: 1. Log Binomial Regression 📈: Specifically designed for prevalence estimation, log binomial regression directly models the prevalence of binary outcomes. By estimating prevalence ratios instead of odds ratios, it offers a more intuitive interpretation of results, making it a preferred choice for prevalence studies in biostatistics. 2. Modified Poisson Regression 🔍: Modified Poisson regression is another powerful tool for prevalence estimation. It provides robust estimates of risk ratios, particularly in studies with common outcomes. By directly modeling the prevalence of binary outcomes, modified Poisson regression offers valuable insights into the risk factors associated with disease prevalence. 3. Probit Regression 📊: Probit regression models the relationship between predictors and binary outcomes using the cumulative distribution function of the standard normal distribution (probit function). It offers an alternative approach to logistic regression while maintaining interpretability, making it suitable for prevalence modeling in biostatistics research. 4. Complementary Log-Log Regression 🔄: Complementary log-log regression extends generalized linear models (GLMs) to capture complex relationships between predictors and binary outcomes. By modeling the logarithm of the negative natural logarithm of the survival function, it provides flexibility in prevalence modeling, particularly for rare events. 5. Generalized Additive Models (GAMs) 🎲: GAMs allow for non-linear relationships between predictors and response variables, enhancing the modeling capabilities beyond logistic regression. By incorporating smooth functions of predictors, GAMs can capture intricate patterns in data, offering valuable insights into the prevalence of binary outcomes in biostatistics research 💡 #biostatistics #dataanalysis #prevalencemodeling #logbinomial #modifiedpoisson

Serving as a Biostatistician in clinical trials and consistently coming across Mixed Model Repeated Measures (MMRM) analysis? It is a powerful tool that deserves a closer look: MMRM is a statistical technique used to analyze data that are collected over time. The "Repeated Measures (RM)" indicates that this model is used when you have collected the same data from a subject over a given period of time (repeatedly). In statistics we have two types of variable effects - fixed and random. When we combine them into the same analysis we call this a "mixed" model. Hence the "MM" in "Mixed Model Repeated Measure". Fixed Effects are consistent components of the data that you expect will impact the outcome, such as the type of treatment administered. Random Effects are random variation in the data that cannot be directly controlled, often due to individual differences among subjects. The equation for MMRM is included in the picture attached to this post where: - Yij is the response variable for the i-th subject at the j-th time point - B0 is the fixed intercept, representing the overall average responses when the predictor X is 0 - b0i is the random intercept for the i-th subject, accounting for individual variability in the baseline response - B1 is the fixed slope, representing the effect of the predictor X on the response Y - b1i is the random slope for the i-th subject, accounting for individual variability in how the response vhanges with the predictor X - Xij is the value of the predictor variable for the i-th subject at the j-th time point - Eij is the residual error for the i-th subject at the j-th time point You can see the fixed effects in the B0 and B1 values and the random effects are the b0i and b1i values (note that random effects have a subject component (i) while fixed efffects do not - this is what makes the MMRM so powerful - when individual differences (random effects) are expected to impact the relationship between variables over time. If you are working as a biostatistician in clinical trials or are looking to make your start - I highly recommend you become familiar with MMRMs. Many study types benefit from them and you are likely to see more and more use out of this tool as percision medicine picks up and random effects take center stage in analyses. If you have any questions about the MMRM and when/how it should be used please do not hesitate to reach out. Happy Tuesday